NEWS

FDA Approves Drug for Patients with Previously Treated Advanced Neuroendocrine Tumors Based on Results from Alliance CABINET Trial

March 26, 2025

Today, the Alliance for Clinical Trials in Oncology was informed that the U.S. Food and Drug Administration has approved cabozantinib for the treatment of patients with previously treated advanced neuroendocrine tumors (NETs). NETs are a type of cancer that manifest characteristics of both nerve and hormone-producing cells, and can arise in


Spotlight on Alliance Colorectal & Bladder Cancer Trials

March 24, 2025

Five important clinical trials focused on innovative treatments for colorectal and bladder cancer are spotlighted in observance of National Colorectal Cancer Awareness Month. These trials aim to improve outcomes and advance cancer care.

  • A022101 (Limited metastatic colorectal cancer)
  • A022104 (Advanced rectal cancer)
  • A031701 (Invasive bladder cancer)
  • A031803 (Non-muscular invasive

A Message from the NCTN Group Chairs: An Emphasis on the Importance of Research Funding

February 21, 2025

Dear Colleagues and Friends,

The Cooperative Groups that come together in the National Clinical Trials Network (NCTN) are responsible for a number of significant advances in cancer treatment arising over the past 40 years. In that time, as published by Unger et al (J Clin Oncol, 2023), this research has led to an estimated 14 million life-years saved for patients with cancer,


Older News